AvenCell Therapeutics Begins Phase I Study for Dual-Targeting CAR-T Therapy in B-Cell Cancer AvenCell Therapeutics has initiated its Phase I QUADvance study for AVC-203, a CAR-T therapy targeting B-cell malignancies, marking a significant milestone.

AvenCell Therapeutics Begins Phase I Study for Dual-Targeting CAR-T Therapy in B-Cell Cancer #USA #CAR-T_therapy #Watertown #AvenCell #AVC-203

AvenCell Therapeutics Secures IND Clearance and EMA Approval for Innovative CAR-T Trial AvenCell Therapeutics has received both FDA's IND clearance and EMA's approval for the QUADvance clinical trial, advancing its promising therapy for B-cell malignancies.

AvenCell Therapeutics Secures IND Clearance and EMA Approval for Innovative CAR-T Trial #USA #Cambridge #CAR-T #AvenCell #AVC-203

AvenCell Receives Up to $40 Million Grant for Allogeneic CAR-T Development AvenCell Japan has been awarded a significant grant to advance its innovative allogeneic CAR-T therapies, addressing critical unmet needs in cancer treatment.

AvenCell Receives Up to $40 Million Grant for Allogeneic CAR-T Development #Japan #Tokyo #CAR-T #AvenCell #AMED

💥 #CELL #THERAPY IN ACTION!! A Diverse & Dynamic group of the people moving the field!! #MoffittBOB #PagonaHealth @iovancebio.bsky.social #Genicity #Galapagos #avencell #Cellares #cancer #immunotherapy #CART #TIL / #Moffitt ROCKS IT with a great program! #SurgeryBranch #NCI #FinishCancer